-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, MSD announced that Luo Wanli will return to MSD, in charge of MSD Human Health International Department, and join the company's executive committee, reporting directly to MSD Global President and CEO Dai Fucai
.
It is reported that Luo Wanli will lead a team of more than 14,000 people and conduct business in 75 markets outside the United States
.
This appointment is effective from August 1, 2022
.
The news of Luo Wanli's return to Merck quickly attracted the attention of the industry
.
According to public information, Luo Wanli has worked at Merck for 25 years and has held many important leadership positions, playing an important role in production, sales, marketing and investor relations
.
In November 2016, Merck announced that Rong Kerui, the company's president of China, had resigned.
Luo Wanli, then managing director of China Taiwan, became the new president of MSD China.
During the four years that Luo Wanli served as the president of MSD China, he managed more than 5,000 employees.
, has been responsible for the launch of more than 20 products including Keytruda and Gardasil, the latter has become a product with outstanding revenue performance of Chinese multinational pharmaceutical companies
.
On June 1, 2021, Luo Wanli, the then president and managing director of MSD China, replaced the former MSD US president Riad EI-Dada as the president of MSD America; but not long after, Luo Wanli chose to leave MSD and join Kei Star Pharmaceuticals, as the company's chief executive officer and a member of its board of directors
.
According to the data, Jixing Pharmaceutical is a start-up biopharmaceutical company headquartered in Shanghai, dedicated to providing innovative drugs for patients suffering from serious life-threatening health diseases.
It was invested and founded by RTW Investments.
In March 2022, the former Chief Operating Officer of Pfizer China Wu Kun also joined the company as chief commercial officer, reporting to Luo Wanli
.
Regarding the return to MSD, Dai Fucai, global president and CEO of MSD, said that Luo Wanli has a deep enough understanding of MSD, and also has rich experience in multiple business divisions and functional departments of MSD, as well as the company headquarters.
Ideal for international leaders
.
It is understood that in MSD China, there have also been cases of executives returning after leaving office, such as Li Zhengqing, general manager of MSD China R&D Center.
In 2019, Li Zhengqing left MSD to join Ascletis Pharmaceuticals as chief medical officer and R&D president of Greater China, but In the same year, he returned to MSD as the head of MSD China R&D Center
.
In addition to Merck, Roche also announced the return of executives not long ago
.
Roche announced that from February 22, 2022, Mr.
Qian Wei will be appointed as the general manager of Roche's oncology business model in China, responsible for Roche's oncology
.
This is also the return of Qian Wei after leaving Roche at the end of June 2021.
In September 2016, Qian Wei joined Roche as the general manager of the first business unit of oncology
.
On June 30, 2021, Qian Wei left Roche and joined Junshi Biotech as CCO in July of the same year, responsible for commercialization planning and business operations
.
Previously, Bian Xin, former president of Roche China, also returned to Roche China after joining BeiGene
.
Behind the return of a group of senior executives of local pharmaceutical companies to multinational pharmaceutical companies, the industry believes that the retention of pharmaceutical talents is often determined by multi-level and complex decision-making.
In recent years, the domestic pharmaceutical environment has improved, and the strength of local companies is also rising.
, attracting the inflow of high-level talents, but foreign executives who take up jobs in local pharmaceutical companies may be “unacceptable” in terms of values, culture, capital, etc.
, so they make the decision to leave
.
For local innovative drug companies, how to retain talents is a question worth thinking about
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is reported that Luo Wanli will lead a team of more than 14,000 people and conduct business in 75 markets outside the United States
.
This appointment is effective from August 1, 2022
.
The news of Luo Wanli's return to Merck quickly attracted the attention of the industry
.
According to public information, Luo Wanli has worked at Merck for 25 years and has held many important leadership positions, playing an important role in production, sales, marketing and investor relations
.
In November 2016, Merck announced that Rong Kerui, the company's president of China, had resigned.
Luo Wanli, then managing director of China Taiwan, became the new president of MSD China.
During the four years that Luo Wanli served as the president of MSD China, he managed more than 5,000 employees.
, has been responsible for the launch of more than 20 products including Keytruda and Gardasil, the latter has become a product with outstanding revenue performance of Chinese multinational pharmaceutical companies
.
On June 1, 2021, Luo Wanli, the then president and managing director of MSD China, replaced the former MSD US president Riad EI-Dada as the president of MSD America; but not long after, Luo Wanli chose to leave MSD and join Kei Star Pharmaceuticals, as the company's chief executive officer and a member of its board of directors
.
According to the data, Jixing Pharmaceutical is a start-up biopharmaceutical company headquartered in Shanghai, dedicated to providing innovative drugs for patients suffering from serious life-threatening health diseases.
It was invested and founded by RTW Investments.
In March 2022, the former Chief Operating Officer of Pfizer China Wu Kun also joined the company as chief commercial officer, reporting to Luo Wanli
.
Regarding the return to MSD, Dai Fucai, global president and CEO of MSD, said that Luo Wanli has a deep enough understanding of MSD, and also has rich experience in multiple business divisions and functional departments of MSD, as well as the company headquarters.
Ideal for international leaders
.
It is understood that in MSD China, there have also been cases of executives returning after leaving office, such as Li Zhengqing, general manager of MSD China R&D Center.
In 2019, Li Zhengqing left MSD to join Ascletis Pharmaceuticals as chief medical officer and R&D president of Greater China, but In the same year, he returned to MSD as the head of MSD China R&D Center
.
In addition to Merck, Roche also announced the return of executives not long ago
.
Roche announced that from February 22, 2022, Mr.
Qian Wei will be appointed as the general manager of Roche's oncology business model in China, responsible for Roche's oncology
.
This is also the return of Qian Wei after leaving Roche at the end of June 2021.
In September 2016, Qian Wei joined Roche as the general manager of the first business unit of oncology
.
On June 30, 2021, Qian Wei left Roche and joined Junshi Biotech as CCO in July of the same year, responsible for commercialization planning and business operations
.
Previously, Bian Xin, former president of Roche China, also returned to Roche China after joining BeiGene
.
Behind the return of a group of senior executives of local pharmaceutical companies to multinational pharmaceutical companies, the industry believes that the retention of pharmaceutical talents is often determined by multi-level and complex decision-making.
In recent years, the domestic pharmaceutical environment has improved, and the strength of local companies is also rising.
, attracting the inflow of high-level talents, but foreign executives who take up jobs in local pharmaceutical companies may be “unacceptable” in terms of values, culture, capital, etc.
, so they make the decision to leave
.
For local innovative drug companies, how to retain talents is a question worth thinking about
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
